311 related articles for article (PubMed ID: 37164926)
21. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database.
Jiang Y; Zhou L; Shen Y; Zhou Q; Ji Y; Zhu H
J Affect Disord; 2024 Feb; 346():223-229. PubMed ID: 37956832
[TBL] [Abstract][Full Text] [Related]
22. Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA adverse event reporting system.
Jiang JJ; Zhao B; Li J
J Clin Pharm Ther; 2022 Oct; 47(10):1556-1562. PubMed ID: 35644838
[TBL] [Abstract][Full Text] [Related]
23. Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.
Fan Q; Hu Y; Wang X; Zhao B
J Neurol; 2021 Jun; 268(6):2169-2174. PubMed ID: 33475824
[TBL] [Abstract][Full Text] [Related]
24. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults.
Nishtala PS; Gill S; Chyou TY
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1689-1695. PubMed ID: 33078448
[TBL] [Abstract][Full Text] [Related]
26. Exploring adverse events of Vilazodone: evidence from the FAERS database.
Jiang Y; Qu Y; Du Z; Ou M; Shen Y; Zhou Q; Tian L; Zhu H
BMC Psychiatry; 2024 May; 24(1):371. PubMed ID: 38755677
[TBL] [Abstract][Full Text] [Related]
27. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
Rong L; Xie M; Jiang M; Qiu H; Kong L
Br J Clin Pharmacol; 2023 Jan; ():. PubMed ID: 36702463
[TBL] [Abstract][Full Text] [Related]
28. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
[TBL] [Abstract][Full Text] [Related]
29. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
30. Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS.
Dai M; Dou X; Chen M; Yang J; Long J; Lin Y
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4105-4121. PubMed ID: 38032491
[TBL] [Abstract][Full Text] [Related]
31. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D
Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539
[TBL] [Abstract][Full Text] [Related]
32. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
33. Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the literature.
Raisch DW; Garg V; Arabyat R; Shen X; Edwards BJ; Miller FH; McKoy JM; Nardone B; West DP
Expert Opin Drug Saf; 2014 Jan; 13(1):15-23. PubMed ID: 24053773
[TBL] [Abstract][Full Text] [Related]
34. Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system.
Cao B; Gu S; Shen Z; Zhang Y; Shen Y; Chen H
Expert Opin Drug Saf; 2024 Mar; 23(3):297-303. PubMed ID: 37608560
[TBL] [Abstract][Full Text] [Related]
35. Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database.
Huang F; San X; Liu Q; Zhu H; Xu W
Sci Rep; 2024 Mar; 14(1):7489. PubMed ID: 38553504
[TBL] [Abstract][Full Text] [Related]
36. Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database.
Wang Q; Qu K; Du Z; Shen Y; Jiang Y; Zhu H
J Psychopharmacol; 2024 Jun; 38(6):562-566. PubMed ID: 38641957
[TBL] [Abstract][Full Text] [Related]
37. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
Chinzowu T; Chyou TY; Nishtala PS
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
[TBL] [Abstract][Full Text] [Related]
38. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
Ren X; Wang H; Deng L; Wang W; Wang Y
Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
[TBL] [Abstract][Full Text] [Related]
39. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
40. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
